Thrombolex Appoints Michael Tutera as Chief Executive Officer

June 15, 2026—Thrombolex, Inc., developer of the Bashir endovascular catheter platform for the pharmacomechanical lysis treatment of pulmonary embolism (PE) and other thromboembolic diseases, announced that the Board of Directors has appointed Michael Tutera as Chief Executive Officer.

The company advised that the appointment comes after the planned transition of Mike Cerminaro, Cofounder and current President & CEO of Thrombolex, who will continue to serve as a member of the Board of Directors.

“I am honored to lead Thrombolex as the company enters an exciting new phase of commercial expansion,” commented Tutera in the company’s press release. “The Bashir endovascular catheter platform represents a differentiated approach to the treatment of PE and other thromboembolic diseases, supported by a growing body of clinical evidence.”

He continued, “With fresh capital, an expanded commercial footprint, and a talented team, Thrombolex is well positioned to broaden physician adoption and improve outcomes for patients. I look forward to building upon the strong foundation and delivering value for patients, physicians, and shareholders.”

Cerminaro added, “We are very fortunate to have someone of Michael’s caliber to lead the company through its next chapter. I am confident that his combination of operating, strategic, and investor expertise makes him exceptionally well positioned to build on the foundation we have created together.”

Thrombolex stated that Tutera brings more than 25 years of healthcare and medical technology leadership experience across commercialization, market access, strategic growth, and investor engagement.

He has held executive leadership roles at Nalu Medical, Intersect ENT, Mallinckrodt Pharmaceuticals, and Forest Laboratories (now AbbVie), and contributed to two successful strategic exits: Intersect ENT’s $1.1 billion acquisition by Medtronic and Nalu Medical’s $600 million acquisition by Boston Scientific, noted the company.